newsfilter
← Latest News
GlobeNewswire·

Replimune Provides Update Following Type A Meeting with FDA

WOBURN, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the